Clinical Trials Logo

Clinical Trial Summary

Individuals who experience high hostility levels may be more prone to developing coronary artery disease (CAD) than individuals who experience low hostility levels. This study will evaluate the effectiveness of a hostility reduction treatment program on the body's ability to regulate heart activity in individuals with high levels of hostility.


Clinical Trial Description

CAD is caused by a narrowing of the blood vessels that supply blood and oxygen to the heart. It is the leading cause of death in the United States. Recent evidence has suggested that individuals with increased hostility levels have a higher risk of developing CAD than individuals with lower hostility levels. The autonomic nervous system (ANS), the involuntary part of the nervous system that is responsible for controlling the body's internal environment in a coordinated manner, may play a role in CAD development. High levels of hostility may elevate ANS activity and increase the release of certain hormones, which in turn may lead to hardening of the arteries and CAD. Cognitive behavioral therapy (CBT) has been effective for treating individuals with hostility. Through CBT, individuals develop coping skills to deal with their anger. This study will evaluate the effect of a CBT hostility reduction treatment program on ANS heart regulation and overall CAD risk in individuals with high levels of hostility.

This study will enroll individuals with high levels of hostility. At an initial screening visit, potential participants will partake in interviews and complete questionnaires to assess hostility levels. Eligible participants will then undergo 24-hour continuous electrocardiogram (ECG) monitoring and will complete questionnaires about their surroundings and any hostility experienced during the 24-hour period. They will also undergo psychophysiological testing, in which responses to a variety of stress-inducing situations will be monitored. Participants will then be randomly assigned to either a 12-week CBT hostility reduction treatment program or a 12-week wait list control group. Participants in the CBT program will attend weekly 75-minute therapy sessions, which will focus on relaxation, stress reduction, behavior management, and development of social, communication, and coping skills. Hostility levels will be documented each day in a diary. Participants in the wait list control group will not take part in any therapy sessions for the initial 12 weeks. At Week 12, baseline evaluations will be repeated for all participants. The waitlist control group will then begin the 12-week CBT program. All participants will attend a 6-month follow-up visit for repeat testing. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00365196
Study type Interventional
Source National Heart, Lung, and Blood Institute (NHLBI)
Contact
Status Completed
Phase N/A
Start date December 1999
Completion date January 2006

See also
  Status Clinical Trial Phase
Completed NCT00069654 - Dietary Nitrate and Nitrite to Increase Nitric Oxide in Patients With Coronary Artery Disease Phase 2
Completed NCT02919124 - Epicardial Echocardiography of Coronary Anastomoses Using the Echoclip Device N/A
Recruiting NCT02639962 - Characteristics of Culprit Lesion and Changes in Plaque Composition. A Dual Energy Cardiac CT Study N/A
Completed NCT02494557 - Risk Stratification for Coronary Artery Disease With Type 2 Diabetic Patients N/A
Recruiting NCT01466452 - Antiplatelet Effect of Low Doses of Aspirin Taken Every 12 Hours in Patients Undergoing Coronary Artery Bypass Graft and/or Aortic Valve Surgery Phase 2
Completed NCT01182428 - XIENCE V: SPIRIT WOMEN Sub-study Phase 4
Completed NCT00371891 - Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS) Phase 4
Completed NCT00368953 - YUKON Choice Versus TAXUS Liberté in Diabetes Mellitus Phase 4
Completed NCT00319449 - Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED) Phase 4
Completed NCT00091754 - Atherosclerosis, Plaque and CVD in Communities
Completed NCT00069797 - Epidemiology of Coronary Heart Disease in Men Aged 40 and Over N/A
Completed NCT00037245 - Androgens and Subclinical Atherosclerosis in Young Women - Ancillary to CARDIA N/A
Completed NCT00024596 - Family Heart Study - Subclinical Atherosclerosis Network (FHS-SCAN) N/A
Withdrawn NCT00006497 - Long-Term Effects of Subclinical CAD on Cardiac Function
Completed NCT00006407 - Sex Steroid Hormones and Risk of CHD in Women N/A
Completed NCT00006502 - Myocardial Perfusion, Risk Factors, and Coronary Calcium N/A
Completed NCT00006309 - Pooling of Cohort Studies on Diet & Coronary Disease N/A
Completed NCT00005269 - Family Blood Pressure Program - GENOA
Completed NCT00000508 - Stanford Coronary Risk Intervention Project (SCRIP) Phase 3
Completed NCT00005147 - Epidemiology of Atherosclerosis N/A